1. Search Result
Search Result
Results for "

Programmed+death+ligand+1

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Peptides

7

Inhibitory Antibodies

20

Recombinant Proteins

7

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9904
    Atezolizumab
    35+ Cited Publications

    MPDL3280A; RG-7446; RO-5541267

    PD-1/PD-L1 Apoptosis Autophagy Cancer
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
    Atezolizumab
  • HY-P99052
    Tislelizumab
    3 Publications Verification

    BGB-A317

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma [1] .
    Tislelizumab
  • HY-P99114

    PD-1/PD-L1 Cancer
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research [1].
    Sugemalimab
  • HY-138139A

    T785 hydrochloride

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
    AXC-715 hydrochloride
  • HY-P3440

    Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1 Cancer
    WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression [1].
    WL12
  • HY-P99723

    BCD-135

    PD-1/PD-L1 Cancer
    Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) [1].
    Manelimab
  • HY-138139B

    T785 trihydrochloride

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist. AXC-715 trihydrochloride can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
    AXC-715 trihydrochloride
  • HY-175323

    Integrin PD-1/PD-L1 Cancer
    NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) [1].
    NOTA-IMB-RGD
  • HY-P990757

    ABL503, TJ-L14B

    PD-1/PD-L1 Inflammation/Immunology
    Ragistomig can simultaneously target programmed death-ligand 1 (PD-L1) and the 4-1BB receptor. Ragistomig elicits potent anti-tumor T-cell responses without inducing significant toxicity. Ragistomig is applicable for tumor research [1].
    Ragistomig
  • HY-P991151

    PD-1/PD-L1 TNF Receptor Cancer
    Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies [1].
    Opamtistomig
  • HY-P991148

    PD-1/PD-L1 Cancer
    Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers [1].
    Moflerafusp alfa
  • HY-179558

    PD-1/PD-L1 Cancer
    MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. MS1-96 effectively reduced PD-L1 protein levels across multiple colorectal cancer (CRC) cell lines. MS1-96 directly binds to PD-L1 (KD = 2.58 μM) and enhances the interaction between HIP1R and PD-L1, thereby altering the intracellular trafficking of PD-L1 within clathrin-coated vesicles. MS1-96 induces abnormal N-glycosylation of PD-L1, destabilizing the protein and hastening its lysosome-mediated degradation. MS1-96 can be used for the study of colorectal cancer [1].
    MS1-96

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: